HALIFAX, Jan. 29, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, today announced
that the Company's Board of Directors was elected at MedMira's 2013
Annual General and Special Meeting of Shareholders, which was held on
January 25th, 2013. Mr. Hermes Chan, Dr. Shou-Ching Tang, Mr. Romano Robusto and
Mr. Markus Meile were re-elected as Directors of the Company. Dr.
Michael Sidler, a representative of the Company's majority shareholder,
OnSite Lab Holding AG, was also elected.
"We are very pleased to welcome Dr. Sidler to our Board of Directors,"
said Hermes Chan, CEO and Director, MedMira. "His expertise in
investment and technology commercialization in early-stage companies
will make a significant contribution to our Board's role in strategic
oversight and business execution as we position ourselves for growth in
Shareholders approved all other matters considered at the meeting
including the appointment of Deloitte as the Company's auditors and
ratification of the stock option plan.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. MedMira is the only Canadian company to
be awarded US Army contracts for the development of rapid tests for HIV
and Hepatitis viruses. The Company's testing solutions provide
hospitals, labs, clinics and individuals with reliable, rapid diagnosis
for diseases such as HIV and hepatitis C in just three minutes. The
Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands
in global markets. MedMira is located in Halifax, Nova Scotia, Canada. www.medmira.com.
This news release contains forward-looking statements, including
statements relating to growth in the Company's business, earnings and
profitability, and trends in demand for the Company's products, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications